EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer

Francesco Passiglia, Francesco Pepe, Gianluca Russo iD, Edoardo Garbo, Angela Listì, Federica Benso iD, Claudia Scimone, Lucia Palumbo, Monica Pluchino, Roberta Minari, Paola Bordi, Massimiliano Cani iD und 11 weitere

Cancer · 2025

DOI: 10.1002/cncr.35917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Francesco Passiglia und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital-Orbassano, Turin, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Lung Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The objective of this study was to investigate the correlation between circulating tumor DNA (ctDNA) KRAS G12C–mutation dynamic variations and treatment outcomes in patients with advanced non‐small cell lung cancer (NSCLC) receiving sotorasib therapy in a real‐world setting.

Methods

Peripheral blood samples were prospectively collected from 32 patients at baseline, at cycle 3, and then at each radiologic assessment during sotorasib treatment. Both tissue and plasma samples were analyzed by using ultra‐deep, customized next‐generation sequencing (NGS) assays. Plasma samples from 27 of 32 patients also were analyzed by digital polymerase chain reaction analysis, and ctDNA dynamic variations were correlated with radiologic responses and patients' clinical outcomes.

Results

A significant correlation between NGS and digital polymerase chain reaction–detected KRAS G12C variant allelic fractions ( p < .001) was observed. Patients who achieved clearance of KRAS G12C–mutant ctDNA levels had a significant improvement in the objective response rate (80% vs. 8%; p < .001), median progression‐free survival (7.9 vs. 2.8 months; p < .001), and median overall survival (16.8 vs. 6.4 months; p < .001) compared with those who did not achieve clearance. The clearance of ctDNA was the only prognostic factor significantly associated with both median progression‐free survival (hazard ratio, 0.15; 95% confidence interval, 0.04–0.48) and median overall survival (hazard ratio, 0.09; 95% confidence interval, 0.02–0.45) in multivariable analysis. Moreover, a dynamic increase in the KRAS G12C median variant allele fraction anticipated radiologic disease progression in 70% of patients who were evaluable at the resistance time point.

Conclusions

This study demonstrated that early clearance of KRAS G12C–mutant ctDNA predicted the clinical benefit of sotorasib in patients with advanced NSCLC, suggesting that dynamic monitoring of ctDNA levels also may anticipate sotorasib resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCirculating Tumor DNALung NeoplasmsProto-Oncogene Proteins p21(ras)PyrimidinesHumansMaleFemaleMiddle AgedAgedMutationHigh-Throughput Nucleotide SequencingProspective StudiesAged, 80 and overBiomarkers, TumorTreatment OutcomePrognosisAdultProgression-Free SurvivalPiperazinesPyridines

Stichwörter der Autor:innen

KRASp.G12Ccirculating tumor DNAliquid biopsynon‐small cell lung cancer (NSCLC)sotorasib

Substanzen

Circulating Tumor DNAProto-Oncogene Proteins p21(ras)KRAS protein, humansotorasibPyrimidinesBiomarkers, TumorPiperazinesPyridines

Autor:innen und Institutionen

  • Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital-Orbassano, Turin, Italy.
  • Department of Public Health, University Federico II of Naples, Naples, Italy.
  • Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Medical Oncology Unit, San Giuseppe Moscati Hospital, Taranto, Italy.
  • Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy.

ORCID-Profile: Gianluca Russo, Federica Benso, Massimiliano Cani, Silvia Novello

Zitieren

APA

Passiglia, F., Pepe, F., Russo, G., Garbo, E., Listì, A., Benso, F., Scimone, C., Palumbo, L., Pluchino, M., Minari, R., Bordi, P., Cani, M., Ungaro, A., Ambrogio, C., Taulli, R., Capelletto, E., Balbi, M., Righi, L., Tiseo, M., …, & Malapelle, U. (2025). Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer. Cancer. https://doi.org/10.1002/cncr.35917

Vancouver

Passiglia F, Pepe F, Russo G, Garbo E, Listì A, Benso F, et al. Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer. Cancer. 2025. doi:10.1002/cncr.35917

BibTeX
@article{Passiglia2025,
  author = {Passiglia, Francesco and Pepe, Francesco and Russo, Gianluca and Garbo, Edoardo and Listì, Angela and Benso, Federica and Scimone, Claudia and Palumbo, Lucia and Pluchino, Monica and Minari, Roberta and Bordi, Paola and Cani, Massimiliano and Ungaro, Antonio and Ambrogio, Chiara and Taulli, Riccardo and Capelletto, Enrica and Balbi, Maurizio and Righi, Luisella and Tiseo, Marcello and Giannarelli, Diana and Troncone, Giancarlo and Novello, Silvia and Malapelle, Umberto},
  title = {Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35917}
}
Kostenlos starten →